Development and validation of an LC-MS/MS method for the determination of mesalazine in beagle dog plasma and its application to a pharmacokinetic study

Biomedical Chromatography

Volumn 29, Issue 2, 2015, Pages 261-267

  Qin, Juan ^a   Di, Xin ^a   Wang, Xin ^a   Liu, Youping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Beagle plasma; LC MS MS; Mesalazine; Pharmacokinetics; Suppository

Indexed keywords

ELECTROSPRAY IONIZATION; MASS SPECTROMETERS; MASS SPECTROMETRY; PRECIPITATION (CHEMICAL);

BEAGLE DOG; BEAGLE PLASMA; DOG PLASMA; ITS APPLICATIONS; LC-MS-MS; LC.MS/MS; MESALAZINE; PHARMACOKINETIC STUDIES; SIMPLE++; SUPPOSITORY;

PHARMACOKINETICS;

DIAZEPAM; MESALAZINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SENSITIVITY ANALYSIS; SUPPOSITORY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; DOG; PROCEDURES;

CANIS FAMILIARIS;

ANIMALS; CHROMATOGRAPHY, LIQUID; DOGS; MESALAMINE; TANDEM MASS SPECTROMETRY;

EID: 84921608539     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3270     Document Type: Article

References (23)

1. Allen L, Weinberger J and Weinberger R. Determination of impurities in the drug 5-aminosalicylic acid by micellar electrokinetic capillary chromatography using an electrolyte pH that approaches the isoelectric point of the parent compound. Journal of Chromatography A 2004; 1053(1-2): 217-226.
2. Bergman R and Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2006; 23(7): 841-855.
3. Brunner M, Lackner E, Exler P, Fluiter H, Kletter K, Tschurlovits M, Dudczak R, Eichler HG and Müller M. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Alimentary Pharmacology and Therapeutics 2006; 23(1): 137-144.
4. Bystrowska B, Nowak J and Brandys J. Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. Journal of Pharmaceutical and Biomedical Analysis 2000; 22(2): 341-347.
5. Chambers E, Wagrowski-Diehl DM, Lu Z and Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. Journal of Chromatography B 2007; 852(1): 22-34.
6. Chungi VS, Rekhi GS and Shargel L. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids. Journal of Pharmaceutical Sciences 1989; 78(3): 235-238.
7. Fischer C, Maier K, Stumpf E, Von Gaisberg U and Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. European Journal of Clinical Pharmacology 1983; 25(4): 511-515.
8. Gandia P, Idier I and Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. The Journal of Clinical Pharmacology 2007; 47(3): 334-342.
9. Gu G-Z, Xia H-M, Pang Z-Q, Liu Z-Y, Jiang X-G and Chen J. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Chromatography B 2011; 879(5): 449-456.
10. Ham M and Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Review of Clinical Pharmacology 2012; 5(2): 113-123.
11. Honoré Hansen S. Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica. Journal of Chromatography B: Biomedical Sciences and Applications 1981; 226(2): 504-509.
12. Hussain F, Ajjan R, Moustafa M, Anderson J and Riley S. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. Journal of Chromatography B: Biomedical Sciences and Applications 1998; 716(1): 257-266.
13. Kloepfer A, Quintana JB and Reemtsma T. Operational options to reduce matrix effects in liquid chromatography-electrospray ionisation-mass spectrometry analysis of aqueous environmental samples. Journal of Chromatography A 2005; 1067(1): 153-160.
14. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clinical Pharmacokinetics 1985; 10(4): 285-302.
15. Laursen LS, Stokholm M, Bukhave K, Rask-Madsen J and Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31(11): 1271-1276.
16. Nobilis M, Vybiralova Z, Sladkova K, Lísa M, Holčapek M and Květina J. High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. Journal of Chromatography A 2006; 1119(1): 299-308.
17. Orioli M, Marinello C, Cozzi R, Piodi LP and Carini M. LC-MS/MS and FT-IR analyses of stones from a patient with Crohn's disease: a case report. Journal of Pharmaceutical and Biomedical Analysis 2004; 35(5): 1263-1272.
18. Palumbo G, Bacchi S, Primavera L, Palumbo P and Carlucci G. A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. Biomedical Chromatography 2005; 19(5): 350-354.
19. Pastorini E, Locatelli M, Simoni P, Roda G, Roda E and Roda A. A Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. Journal of Chromatography B 2008; 872(1): 99-106.
20. Trufelli H, Palma P, Famiglini G and Cappiello A. An overview of matrix effects in liquid chromatography-mass spectrometry. Mass Spectrometry Reviews 2011; 30(3): 491-509.
21. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001.
22. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I and Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. Journal of Chromatography B 2009; 877(23): 2198-2207.
23. Wilding I, Behrens C, Tardif S, Wray H, Bias P and Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Alimentary Pharmacology and Therapeutics 2003; 17(9): 1153-1162.